Skip to main content

Advertisement

Log in

Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs as Therapies for Osteoporosis

  • Hot Topic
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Osteoporotic fractures result in significant morbidity and mortality. Anabolic agents reverse the negative skeletal balance that characterizes osteoporosis by stimulating osteoblast-dependent bone formation to a greater degree than osteoclast-dependent bone resorption. Parathyroid hormone (PTH) and parathyroid hormone- related protein (PTHrP) are peptide hormones, which have anabolic actions when administered intermittently. The only FDA-approved anabolic bone agent for the treatment of osteoporosis in the United States is PTH 1-34, or teriparatide, administered by daily subcutaneous injections. However, PTH 1-84 is also available in Europe. Synthetic human PTHrP 1-36 and a PTHrP 1-34 analog, BA058, have also been shown to increase lumbar spine bone density. These agents and several other PTH and PTHrP analogs, including some which are not administered as injections, continue to be investigated as potential anabolic therapies for osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276–87.

    Article  PubMed  CAS  Google Scholar 

  2. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–95.

  3. WHO Scientific Group on the assessment of osteoporosis at primary health care level. Available at http://www.who.int/chp/topics/Osteoporosis.pdf. Accessed May 2013.

  4. Dempster DW, Zhou H, Recker RR, et al. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97:2799–808.

    Article  PubMed  CAS  Google Scholar 

  5. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73–9.

    Article  PubMed  CAS  Google Scholar 

  6. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437–43.

    Article  PubMed  CAS  Google Scholar 

  7. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–45.

    Article  PubMed  CAS  Google Scholar 

  8. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–52.

    Article  PubMed  CAS  Google Scholar 

  9. McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012;27:1480–6.

    Article  PubMed  CAS  Google Scholar 

  10. Migliore A, Broccoli S, Massafra U, et al. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis. Curr Med Res Opin. 2012;28:467–73.

    Article  PubMed  CAS  Google Scholar 

  11. Esbrit P, Alcaraz MJ. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. Biochem Pharmacol. 2013;85:1417–23.

    Article  PubMed  CAS  Google Scholar 

  12. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26:688–703.

    Article  PubMed  CAS  Google Scholar 

  13. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905–16.

    Article  PubMed  CAS  Google Scholar 

  14. Frolik CA, Black EC, Cain RL, et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone. 2003;33:372–9.

    Article  PubMed  CAS  Google Scholar 

  15. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846–53.

    Article  PubMed  CAS  Google Scholar 

  16. Frost ML, Siddique M, Blake GM, et al. Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography. J Bone Miner Res. 2011;26:1002–11.

    Article  PubMed  CAS  Google Scholar 

  17. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997;138:4607–12.

    Article  PubMed  CAS  Google Scholar 

  18. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40:1434–46.

    Article  PubMed  CAS  Google Scholar 

  19. • Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012;27:2419–28. This review article summarizes available data about the safety of teriparatide and PTH 1-84 including risk of osteosarcoma.

    Article  PubMed  Google Scholar 

  20. Dean T, Vilardaga JP, Potts Jr JT, et al. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol. 2008;22:156–66.

    Article  PubMed  CAS  Google Scholar 

  21. •• Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab. 2012;97:2947–56. This review article summarizes PTHrP functions throughout the body with particular focus on research from the past decade.

    Article  PubMed  CAS  Google Scholar 

  22. Philbrick WM, Wysolmerski JJ, Galbraith S, et al. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev. 1996;76:127–73.

    PubMed  CAS  Google Scholar 

  23. Miao D, Li J, Xue Y, et al. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology. 2004;145:3554–62.

    Article  PubMed  CAS  Google Scholar 

  24. Horwitz MJ, Tedesco MB, Sereika SM, et al. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003;88:1603–9.

    Article  PubMed  CAS  Google Scholar 

  25. Stewart AF, Cain RL, Burr DB, et al. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res. 2000;15:1517–25.

    Article  PubMed  CAS  Google Scholar 

  26. de Castro LF, Lozano D, Portal-Nunez S, et al. Comparison of the skeletal effects induced by daily administration of PTHrP (1-36) and PTHrP (107-139) to ovariectomized mice. J Cell Physiol. 2012;227:1752–60.

    Article  PubMed  Google Scholar 

  27. Horwitz MJ, Tedesco MB, Gundberg C, et al. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88:569–75.

    Article  PubMed  CAS  Google Scholar 

  28. •• Horwitz MJ, Augustine M, Kahn L, et al. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J Bone Miner Res. 2013. doi:10.1002/jbmr.1978. This paper describes the results of the first randomized, controlled trial comparing the effects daily subcutaneous PTHrP 1-36 or teriparatide administration on bone turnover markers and bone density in women with postmenopausal osteoporosis.

    PubMed  Google Scholar 

  29. Horwitz MJ, Tedesco MB, Garcia-Ocana A, et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab. 2010;95:1279–87.

    Article  PubMed  CAS  Google Scholar 

  30. Eli Lilly and Company: Forteo Prescribing information. Available at http://pi.lilly.com/us/forteo-pi.pdf. Accessed June 2013.

  31. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.

    Article  PubMed  CAS  Google Scholar 

  32. Gold DT, Pantos BS, Masica DN, et al. Initial experience with teriparatide in the United States. Curr Med Res Opin. 2006;22:703–8.

    Article  PubMed  CAS  Google Scholar 

  33. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146:326–39.

    Article  PubMed  Google Scholar 

  34. •• Hansen S, Hauge EM, Beck Jensen JE, et al. Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res. 2013;28:736–45. This study demonstrates the benefits of anabolic therapy as opposed to bisphosphonate use on bone microarchitecture and strength.

    Article  PubMed  CAS  Google Scholar 

  35. • Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98:137–44. This study describes the effects of extended use of PTH 1-84 for treatment of hypoparathyroidism.

    Article  PubMed  CAS  Google Scholar 

  36. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312–21.

    Article  PubMed  CAS  Google Scholar 

  37. • Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429–37. These are findings from US postmarketing data for teriparatide, indicating that teriparatide is a safe treatment.

    Article  PubMed  CAS  Google Scholar 

  38. Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med. 2003;19:415–32.

    Article  PubMed  Google Scholar 

  39. Finkelstein JS, Wyland JJ, Leder BZ, et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab. 2009;94:2495–501.

    Article  PubMed  CAS  Google Scholar 

  40. Leder BZ, Neer RM, Wyland JJ, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009;94:2915–21.

    Article  PubMed  CAS  Google Scholar 

  41. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353:555–65.

    Article  PubMed  CAS  Google Scholar 

  42. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216–26.

    Article  PubMed  CAS  Google Scholar 

  43. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745–51.

    Article  PubMed  CAS  Google Scholar 

  44. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23:1591–600.

    Article  PubMed  CAS  Google Scholar 

  45. Jakob F, Oertel H, Langdahl B, et al. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol. 2012;166:87–97.

    Article  PubMed  CAS  Google Scholar 

  46. • Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:503–11. This study demonstrates effect of IV bisphosphonate in combination with teriparatide compared with either therapy alone, suggesting that combination therapy may provide the most benefit when hip and spine are both considered.

    Article  PubMed  CAS  Google Scholar 

  47. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207–15.

    Article  PubMed  CAS  Google Scholar 

  48. Finkelstein JS, Wyland JJ, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95:1838–45.

    Article  PubMed  CAS  Google Scholar 

  49. Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res. 2009;24:1110–5.

    Article  PubMed  Google Scholar 

  50. Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women. Available at: http://www.clinicaltrials.gov/ct2/show/study/NCT01343004?term=ba058&rank=3. Accessed May 2013.

  51. Hattersley G, Bilezikian J, Guerriero J, et al, (Eds). Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: results from a phase 2 clinical trial in postmenopausal women with osteoporosis. The Endocrine Society's 94th Annual Meeting; Houston. 2012.

  52. • Zhang D, Potty A, Vyas P, et al. The role of recombinant Pth in human fracture healing: a systematic review. J Orthop Trauma. 2013; [Epub ahead of print] PMID 23454854. This paper reviews the case reports and RCTs to date exploring use of PTH analogs in fracture healing.

  53. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25:404–14.

    Article  PubMed  CAS  Google Scholar 

  54. Peichl P, Holzer LA, Maier R, et al. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93:1583–7.

    Article  PubMed  Google Scholar 

  55. Nakamura T, Sugimoto T, Nakano T, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097–106.

    Article  PubMed  CAS  Google Scholar 

  56. Sugimoto T, Shiraki M, Nakano T, et al. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin. 2013;29:195–203.

    Article  PubMed  CAS  Google Scholar 

  57. Henriksen K, Andersen JR, Riis BJ, et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone. 2013;53:160–6.

    Article  PubMed  CAS  Google Scholar 

  58. Hammerle SP, Mindeholm L, Launonen A, et al. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone. 2012;50:965–73.

    Article  PubMed  CAS  Google Scholar 

  59. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95:151–8.

    Article  PubMed  CAS  Google Scholar 

  60. Matsumoto T, Shiraki M, Hagino H, et al. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos Int. 2006;17:1532–8.

    Article  PubMed  CAS  Google Scholar 

  61. Farra R, Sheppard Jr NF, McCabe L, et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med. 2012;4:122ra121.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

M Augustine works for an institution that has received an NIH grant.

MJ Horwitz works for an institution that has received an NIH grant, is an NPS consultant, and has received royalties as a chapter author for Up To Date.

Human and Animal Rights and Informed Consent

Informed consent, approved by the University of Pittsburgh IRB, was obtained from each subject in cited studies performed by the authors (24, 27-29).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mara J. Horwitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Augustine, M., Horwitz, M.J. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs as Therapies for Osteoporosis. Curr Osteoporos Rep 11, 400–406 (2013). https://doi.org/10.1007/s11914-013-0171-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-013-0171-2

Keywords

Navigation